FDA's Oncologic Drugs Advisory Committee has voted 12 to 2 in favor of imetelstat for patients with LR-MDS. Read why Geron ...

Fintel reports that on April 30, 2024, Baird downgraded their outlook for Geron (NasdaqGS:GERN) from Outperform to Neutral. ...

It's the holy grail for some people: how to possibly slow aging or wind back our body's biological clock despite the years ...

Tarlatamab is an investigational first-in-class, bispecific T-cell engager immunotherapy designed to target delta-like ligand 3 on small cell lung cancer (SCLC) cells and CD3 on T cells. The ...

Vlad Vitoc, M.D., MAIA’s Chairman and Chief Executive Officer, commented, "As a top investor in MAIA, we extend our deep ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The economy is currently on a stable trajectory and is poised ...

Discover Amicus Therapeutics' groundbreaking patent for treating Fabry disease with migalastat, targeting specific mutations in a-galactosidase A. Learn about the innovative method and potential ...

MAIA entered into definitive agreements for the purchase and sale of an aggregate of 494,096 shares of common stock at a purchase price of $2.034 per share, in a private placement to accredited ...

Discover a groundbreaking patent for treating lung cancer with specific TIM-3 binding agents and anti-PD-1 antibodies. Learn about the dosage regimen and administration process for effective treatment ...

New research presents a significant discovery: small extracellular vesicles (sEVs) from the blood of young mice possess the ...

Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financi ...